共 50 条
Live attenuated Salmonella enterica serovar Choleraesuis vector delivering a virus-like particles induces a protective immune response against porcine circovirus type 2 in mice
被引:1
|作者:
Li, Yu-an
[1
,2
]
Sun, Yanni
[2
]
Zhang, Yuqin
[1
,2
]
Wang, Shifeng
[3
]
Shi, Huoying
[1
,2
,4
]
机构:
[1] Yangzhou Univ, Coll Vet Med, Yangzhou 225009, Jiangsu, Peoples R China
[2] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Jiangsu, Peoples R China
[3] Univ Florida, Dept Infect Dis & Immunol, Coll Vet Med, Gainesville, FL 32611 USA
[4] Yangzhou Univ JIRLAAPS, Joint Int Res Lab Agr & Agri Prod Safety, Yangzhou, Jiangsu, Peoples R China
来源:
基金:
中国国家自然科学基金;
关键词:
Virus-like particles;
Attenuated S. Choleraesuis vector;
Cap protein;
PCV2;
vaccine;
REGULATED DELAYED ATTENUATION;
STREPTOCOCCUS-SUIS;
PCV2;
VACCINE;
EXPRESSION;
GENERATION;
ANTIBODY;
MOUSE;
PIGS;
IMMUNOGENICITY;
NEUTRALIZATION;
D O I:
暂无
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
The virus-like particles (VLPs) of porcine circovirus type 2 (PCV2) is an attractive vaccine candidate that retains the natural conformation of the virion but lacks the viral genome to replicate, thus balancing safety and immunogenicity. However, the assembly of VLPs requires cumbersome subsequent processes, hindering the development of related vaccines. In addition, as a subunit antigen, VLPs are defective in inducing cellular and mucosal immune responses. In this study, the capsid (Cap) protein of PCV2 was synthesized and self-assembled into VLPs in the recombinant attenuated S. Choleraesuis vector, rSC0016(pSCap). Furthermore, rSC0016(pS-Cap) induced a Cap-specific Th1-dominant immune response, mucosal immune responses, and neutralizing antibodies against PCV2. Finally, the virus genome copies in mice immunized with the rSC0016(pS-Cap) were significantly lower than those of the empty vector control group after challenge with PCV2. In conclusion, our study demonstrates the potential of using S. Choleraesuis vectors to delivery VLPs, providing new ideas for the development of PCV2 vaccines. (c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4732 / 4741
页数:10
相关论文